Regeneron (REGN) Down as Q4 Eylea Preliminary Sales Disappoint

Shares of Regeneron Pharmaceuticals, Inc. (REGN) declined 1.13% after the company reported disappointing fourth-quarter preliminary sales for lead drug, Eylea.Sales of Eylea (aflibercept) and Eylea HD (higher dose of Eylea) came in at $1.46 billion in the United States. The Zacks Consensus Estimate for the same was $1.45 billion.Eylea sales came in at $1.34 billion in the United States and Eylea HD sales came in at $123 million in the fourth quarter of 2023. This was the first full quarter for Eylea HD foll ...